Jennifer Ortega

Energetic and detail-oriented professional with strong background in healthcare management and team leadership. In-depth understanding of clinical processes and regulatory compliance, combined with proficiency in project management and strategic planning. Committed to driving operational efficiency and enhancing patient care outcomes.

• Good Clinical Practice With Investigational Drugs and Medical Devices CITI Program
• Basic CPR - 2024
• Registered Nurse RN 9543228

• Ocugen, Inc. - A Phase 2/3, Observer-Blind, Immuno-bridging, and Broadening Study of a Whole, Inactivated XXX-XX Vaccine (XXXX) in Healthy Adults
• Merck Sharp & Dohme LLC - A Phase 3 Randomized, Double-blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of XXX When Administered Concomitantly with Influenza Vaccine in Adults 50 Years of Age or Older
• Sanofi Pasteur Inc. - Safety and Immunogenicity of XXX XXXX XXX XXXX in Adults Aged 18 Years and Older
• PFIZER - A PHASE 1, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ORALLY ADMINISTERED XXX/XXX IN PREGNANT WOMEN WITH MILD-TOMODERATE COVID-19
• ET HEALTHCARE - ET Healthcare COVID-19 OTC Home Use Antigen Self-Test Clinical Study
• ZYDUS THERAPEUTICS, INC - A Phase 2b, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of XXXX XX in Subjects with Nonalcoholic Steatohepatitis and Fibrosis
• BAVARIAN NORDIC - Evaluation of the Immunogenicity, Safety, and Tolerability of a Single Dose of XXXX Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2: a Phase 3 Trial in Two Parts—Randomized, Double-blind, Active Controlled and Open-label, Single-arm
• GEORGE MEDICINES - Efficacy and safety of XXX compared to dual combinations for the treatment of hypertension
• GEORGE MEDICINES - Efficacy and safety of XXX compared to placebo for the treatment of Hypertension
• GlaxoSmithKline Research & Development Limited - A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of XXXX to XXX in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
• MODERNA TX, INC - A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity XXXX Vaccine in Adults Aged 18 Years and Older
• MODERNA TX, INC - A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of XXXX, XXX Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine in Adults ≥ 50 Years of Age
• JANSSEN VACCINES & PREVENTION B.V - A Randomized, Double-blind, Placebo-controlled Phase 3 Efficacy Study of an XXX.XX-based Vaccine in the Prevention of Lower Respiratory Tract Disease Caused by RSV in Adults Aged 60 Years and Older
• JANSSEN VACCINES & PREVENTION B.V - A Randomized, Double-blind Phase 3 Study to Assess the Immunogenicity and Safety of an XXXX.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 Years
• JANSSEN VACCINES & PREVENTION B.V - A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of XX.XXXX for the Prevention of SARS-CoV2-mediated COVID-19 in Adults Aged 18 Years and Older
• JANSSEN VACCINES & PREVENTION B.V - A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of XXX for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older
• NOVARTIS - A randomized, placebo-controlled, participant-and investigator-blinded, sponsor open label study to evaluate the safety, tolerability, and efficacy with different dosing regimens of subcutaneously administered XXXXX in obese participants with or without type 2 diabetes mellitus
• PFIZER- A PHASE 1/2 RANDOMIZED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A XXX XXX AGAINST INFLUENZA IN HEALTHY INDIVIDUALS
• GLAXOSMITHKLINE - A study on the immune response and safety of the XXXX vaccine and the influenza vaccine when either is given to healthy adults at the same time or following a COVID-19 booster vaccine.
• GENENTECH, INC - A PHASE IIb, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF XXX IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
• NOVAVAX, INC. - A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a XXX-XX-X Recombinant Spike Protein Nanoparticle Vaccine (XXX) with XXX Adjuvant in Adult Participants ≥ 18 Years with a Pediatric Expansion in Adolescents (12 to < 18 Years)
• ELI-LILLY- An Early Feasibility Study to Evaluate the Safety and Functionality of an Individual Accruing Data Algorithm with XXXX in Adult Participants with Type 2 Diabetes
• Avalo Therapeutics, Inc. - A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of XXXX for the Treatment of Poorly Controlled Non-Eosinophilic Asthma
• ELI-LILLY - A Master Protocol for Randomized, Placebo-Controlled, Phase 2 Clinical Trials of Multiple Interventions for the Treatment of Chronic Pain
• Sanofi Pasteur Inc. - Immunogenicity and Safety of the First-in-Human XXXX Vaccine Formulation in Healthy Adults 18 Years of Age and Older
• Pfizer - A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED XXX/XXX IN PREVENTING SYMPTOMATIC SARS-COV-2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID-19
• Pfizer - AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2/3, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED XXXX/XXX COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID-19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS
• Novartis- A Phase I/III Randomized, Double-blind Study to Evaluate the Safety, Efficacy, and Neutralizing Activity of xxxxxx for Pre-exposure Prophylaxis of COVID-19 in Participants with Conditions Causing Immune Impairment
• Boehringer Ingelheim- A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with xxxx administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD
• NeuroBo- A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL, PHASE 2A CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF DA-1241 IN SUBJECTS WITH PRESUMED NON-ALCOHOLIC STEATOHEPATITIS (NASH)
• SHIONOGI - A Phase 2, multicenter, randomized, double-blind, dose-ranging, placebo-controlled study to assess the safety and efficacy of xxxx in obese adults
• MODERNA- A Phase 3, Randomized, Observer-blind, Active-control Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of XXXX (SARS-Cov-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age